SCHEMBL26580703

SCHEMBL26580703

COCC(COC)CC(=O)OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.43
HSD17B10 Q99714 2/20 0.40
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
KMT2A Q03164 2/20 0.33
TET2 Q6N021 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 3/20 0.33
RAB9A P51151 1/20 0.33
LMNA P02545 2/20 0.32
CA12 O43570 1/20 0.32
CA14 Q9ULX7 1/20 0.32
KDM4E B2RXH2 1/20 0.32
RECQL P46063 1/20 0.32
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32
ALDH1A1 P00352 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3197402 0.84 TSHR (0.53) TSHRHSD17B10MGAMGAASI
SCHEMBL31292947 0.79 MGAM (0.46) TSHRHSD17B10MGAMGAASI
SCHEMBL3676085 0.78 TSHR (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL3676083 0.78 TSHR (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL13296224 0.78 TSHR (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL25600165 0.78 TSHR (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL7888718 0.77 TSHR (0.46) TSHRHSD17B10MGAMGAASI
SCHEMBL16256492 0.77 TSHR (0.46) TSHRHSD17B10MGAMGAASI
SCHEMBL13039797 0.77 ALDH1A1 (0.43) MGAMGAASIMGAM2ALDH1A1
SCHEMBL5000149 0.77 TSHR (0.46) TSHRHSD17B10MGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024040194-A1 CONDITIONING FOR IN VIVO IMMUNE CELL ENGINEERING CAPSTAN THERAPEUTICS, INC. (US) 2024-02-22 WO disclosed
WO-2024040195-A1 CONDITIONING FOR IN VIVO IMMUNE CELL ENGINEERING CAPSTAN THERAPEUTICS, INC. (US) 2024-02-22 WO disclosed
WO-2023196445-A1 PEG-LIPIDS AND LIPID NANOPARTICLES CAPSTAN THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed